FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
2021年5月5日 · KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test.
FDA approves neoadjuvant/ adjuvant pembrolizumab for …
On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of...
FDA approves pembrolizumab with chemotherapy for HER2 …
On November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults...
FDA approves pembrolizumab as adjuvant treatment for non …
On January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
2023年11月16日 · KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
2024年6月17日 · KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status. Approval marks the third FDA-approved indication for KEYTRUDA in endometrial carcinoma and …
Adjuvant Keytruda Improves Kidney Cancer Survival - NCI
2024年5月21日 · The immunotherapy drug pembrolizumab (Keytruda) has rapidly become one of the most widely used cancer treatments. Based on updated results from a large clinical trial, the drug is now part of an important milestone in the treatment of kidney cancer—specifically, clear-cell renal cell carcinoma, the most common form of the disease.
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA …
2024年3月21日 · KEYLYNK-006 is a randomized, open-label, two-phase Phase 3 trial (ClinicalTrials.gov, NCT03976323) evaluating KEYTRUDA in combination with chemotherapy (pemetrexed plus carboplatin or cisplatin...
Merck wins first FDA approval for Keytruda as a treatment for ...
2024年9月18日 · Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated...
Padcev and Keytruda Double Bladder Cancer Survival - NCI
2023年11月30日 · One treatment—the combination of enfortumab vedotin (Padcev) and the immunotherapy drug pembrolizumab (Keytruda) —proved to be particularly powerful. The findings mark a pivotal moment following years of little progress, according to …